Modifying dendritic cells via protein transfer for antitumor therapeutics

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 283-291

  Liu, Shanrong ^a,b   Foster, Barbara A ^c   Chen, Tie ^a   Zheng, Guoxing ^a   Chen, Aoshuang ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYTOKINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOSTIMULATING AGENT; PROTEIN TRANCE; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CELL INFILTRATION; CELL MIGRATION; CELL POPULATION; DENDRITIC CELL; FEMALE; IN VIVO STUDY; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN TRANSPORT; T LYMPHOCYTE; TH1 CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CANCER VACCINES; CELL TRANSPLANTATION; DENDRITIC CELLS; FEMALE; FLUORESCEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; SUCCINIMIDES; TH1 CELLS; TIME FACTORS;

EID: 33846331238     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1913     Document Type: Article

References (44)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104:2235-46.
3. Matsue H, Morita A, Matsue K, Takashima A. New technologies toward dendritic cell-based cancer immunotherapies. J Dermatol 1999;26:757-63.
4. Sprinzl GM, Kacani L, Schrott-Fischer A, Romani N, Thumfart WF. Dendritic cell vaccines for cancer therapy. Cancer Treat Rev 2001;27:247-55.
5. Mercier GT, Campbell JA, Chappell JD, Stehle T, Dermody TS, Barry MA. A chimeric adenovirus vector encoding reovirus attachment protein σ1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci U S A 2004;101:6188-93.
6. Muraro S, Bondanza A, Bellone M, Greenberg PD, Bonini C. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood 2005;105:3596-604.
7. Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH. Gene modification strategies to induce tumor immunity. Immunity 2005;22:403-14.
8. Larin SS, Georgiev GP, Kiselev SL. Gene transfer approaches in cancer immunotherapy. Gene Ther 2004;11 Suppl 1:S18-25.
9. Collins MK, Cerundolo V. Gene therapy meets vaccine development. Trends Biotechnol 2004;22:623-6.
10. Chen A, Zheng G, Tykocinski ML. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J Immunol 2000;164:705-11.
11. Zheng G, Chen A, Sterner RE, et al. Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 2001;61:8127-34.
12. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
13. Chen A, Xu H, Choi Y, Wang B, Zheng G. TRANCE counteracts FasL-mediated apoptosis of murine bone marrow-derived dendritic cells. Cell Immunol 2004; 231:40-8.
14. Kim YJ, Kim SH, Mantel P, Kwon BS. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol 1998;28:881.
15. Zheng G, Liu S, Wang P, Xu Y, Chen A. Arming tumor-reactive T cells with costimulator b7-1 enhances therapeutic efficacy of the T cells. Cancer Res 2006; 66:6793-9.
16. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447.
17. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
18. Anderson D-M, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1998;390:175-9.
19. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47.
20. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003;4:579-85.
21. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002;100:1734-41.
22. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
23. Smith AL, Fazekas de St Groth B. Antigen-pulsed CD8α+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 1999;189:593-8.
24. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ Tcell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000;164:3095-101.
25. Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647.
26. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
27. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
28. Lappin MB, Weiss JM, Delattre V, et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98:181-8.
29. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 2005;17: 187-94.
30. Mathis D, Benoist C. Back to central tolerance. Immunity 2004;20:509-16.
31. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit Rev Immunol 2001;21:133-45.
32. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311-6.
33. Menges M, Rossner S, Voigtlander C, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002;195: 15-21.
34. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1α25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:6800-5.
35. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2:1010-7.
36. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
37. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-80.
38. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400.
39. Ingulli E, Mondino A, Lhoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4+ Tcells. J Exp Med 1997;185:2133-41.
40. Tykocinski ML, Shu HK, Ayers DJ, et al. Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci U S A 1988;85: 3555-9.
41. Huang JH, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994;1: 607-13.
42. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995;92:8059-63.
43. Tykocinski ML, Chen A, Huang JH, Weber MC, Zheng G. New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints. Immunol Res 2003;27:565-74.
44. Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol Res 2004;29:231-40.